346 related articles for article (PubMed ID: 27865300)
21. Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study.
Solini A; Giannini L; Seghieri M; Vitolo E; Taddei S; Ghiadoni L; Bruno RM
Cardiovasc Diabetol; 2017 Oct; 16(1):138. PubMed ID: 29061124
[TBL] [Abstract][Full Text] [Related]
22. Empagliflozin ameliorates symptoms of diabetes and renal tubular dysfunction in a rat model of diabetes with enlarged kidney (DEK).
Domon A; Katayama K; Sato T; Tochigi Y; Tazaki H; Suzuki H
PLoS One; 2021; 16(5):e0251135. PubMed ID: 33945582
[TBL] [Abstract][Full Text] [Related]
23. SGLT2 inhibition versus sulfonylurea treatment effects on electrolyte and acid-base balance: secondary analysis of a clinical trial reaching glycemic equipoise: Tubular effects of SGLT2 inhibition in Type 2 diabetes.
van Bommel EJM; Geurts F; Muskiet MHA; Post A; Bakker SJL; Danser AHJ; Touw DJ; van Berkel M; Kramer MHH; Nieuwdorp M; Ferrannini E; Joles JA; Hoorn EJ; van Raalte DH
Clin Sci (Lond); 2020 Dec; 134(23):3107-3118. PubMed ID: 33205810
[TBL] [Abstract][Full Text] [Related]
24. Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy.
Arow M; Waldman M; Yadin D; Nudelman V; Shainberg A; Abraham NG; Freimark D; Kornowski R; Aravot D; Hochhauser E; Arad M
Cardiovasc Diabetol; 2020 Jan; 19(1):7. PubMed ID: 31924211
[TBL] [Abstract][Full Text] [Related]
25. Expression of transporters involved in urine concentration recovers differently after cessation of lithium treatment.
Blount MA; Sim JH; Zhou R; Martin CF; Lu W; Sands JM; Klein JD
Am J Physiol Renal Physiol; 2010 Mar; 298(3):F601-8. PubMed ID: 20032119
[TBL] [Abstract][Full Text] [Related]
26. The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Renal and Liver Disease in Western Diet Induced Obesity Mice.
Wang D; Luo Y; Wang X; Orlicky DJ; Myakala K; Yang P; Levi M
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29301371
[TBL] [Abstract][Full Text] [Related]
27. Dapagliflozin Does Not Protect against Adriamycin-Induced Kidney Injury in Mice.
Cha JJ; Park HJ; Yoo JA; Ghee J; Cha DR; Kang YS
Kidney Blood Press Res; 2024; 49(1):81-90. PubMed ID: 38185119
[TBL] [Abstract][Full Text] [Related]
28. Dapagliflozin Aggravates Renal Injury via Promoting Gluconeogenesis in db/db Mice.
Jia Y; He J; Wang L; Su L; Lei L; Huang W; Geng X; Zhang S; Meng X; Zhou H; Yang B
Cell Physiol Biochem; 2018; 45(5):1747-1758. PubMed ID: 29495021
[TBL] [Abstract][Full Text] [Related]
29. Increased renal ENaC subunit and sodium transporter abundances in streptozotocin-induced type 1 diabetes.
Song J; Knepper MA; Verbalis JG; Ecelbarger CA
Am J Physiol Renal Physiol; 2003 Dec; 285(6):F1125-37. PubMed ID: 12904328
[TBL] [Abstract][Full Text] [Related]
30. Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.
Davidson JA; Kuritzky L
Postgrad Med; 2014 Oct; 126(6):33-48. PubMed ID: 25414933
[TBL] [Abstract][Full Text] [Related]
31. Urine concentration in the diabetic mouse requires both urea and water transporters.
Ilori TO; Blount MA; Martin CF; Sands JM; Klein JD
Am J Physiol Renal Physiol; 2013 Jan; 304(1):F103-11. PubMed ID: 23136000
[TBL] [Abstract][Full Text] [Related]
32. Impaired distal renal potassium handling in streptozotocin-induced diabetic mice.
Wu P; Li ST; Shu TT; Mao ZH; Fu WJ; Yang YY; Pan SK; Liu DW; Liu ZS; Gao ZX
Am J Physiol Renal Physiol; 2024 Jul; 327(1):F158-F170. PubMed ID: 38779755
[TBL] [Abstract][Full Text] [Related]
33. Dapagliflozin attenuates early markers of diabetic nephropathy in fructose-streptozotocin-induced diabetes in rats.
Oraby MA; El-Yamany MF; Safar MM; Assaf N; Ghoneim HA
Biomed Pharmacother; 2019 Jan; 109():910-920. PubMed ID: 30551545
[TBL] [Abstract][Full Text] [Related]
34. Dapagliflozin suppresses glucagon signaling in rodent models of diabetes.
Wang MY; Yu X; Lee Y; McCorkle SK; Chen S; Li J; Wang ZV; Davidson JA; Scherer PE; Holland WL; Unger RH; Roth MG
Proc Natl Acad Sci U S A; 2017 Jun; 114(25):6611-6616. PubMed ID: 28584109
[TBL] [Abstract][Full Text] [Related]
35. Sodium-Glucose Linked Cotransporter-2 Inhibition Does Not Attenuate Disease Progression in the Rat Remnant Kidney Model of Chronic Kidney Disease.
Zhang Y; Thai K; Kepecs DM; Gilbert RE
PLoS One; 2016; 11(1):e0144640. PubMed ID: 26741142
[TBL] [Abstract][Full Text] [Related]
36. Dapagliflozin improves steatohepatitis in diabetic rats via inhibition of oxidative stress and inflammation.
Hazem RM; Ibrahim AZ; Ali DA; Moustafa YM
Int Immunopharmacol; 2022 Mar; 104():108503. PubMed ID: 34998036
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of Mitiglinide Combined with Dapagliflozin in Streptozotocin-nicotinamide-induced Type 2 Diabetic Rats and in Zucker Fatty Rats.
Akahane K; Inoue T; Yokoyama A; Yaguchi A; Ojima K; Kiguchi S; Maruyama K; Kobayashi M; Mori Y
Drug Res (Stuttg); 2015 Aug; 65(8):416-21. PubMed ID: 25188606
[TBL] [Abstract][Full Text] [Related]
38. Upregulation of renal Na-K-2Cl cotransporter 2 in obese diabetes mellitus via a vasopressin receptor 2-dependent pathway.
Sakai K; Yamazaki O; Ishizawa K; Tamura Y; Wang Q; Ueno M; Hayama Y; Fujigaki Y; Shibata S
Biochem Biophys Res Commun; 2020 Apr; 524(3):710-715. PubMed ID: 32035616
[TBL] [Abstract][Full Text] [Related]
39. Sildenafil reduces polyuria in rats with lithium-induced NDI.
Sanches TR; Volpini RA; Massola Shimizu MH; Bragança AC; Oshiro-Monreal F; Seguro AC; Andrade L
Am J Physiol Renal Physiol; 2012 Jan; 302(1):F216-25. PubMed ID: 22031848
[TBL] [Abstract][Full Text] [Related]
40. Dapagliflozin Suppresses ER Stress and Improves Subclinical Myocardial Function in Diabetes: From Bedside to Bench.
Shih JY; Lin YW; Fisch S; Cheng JT; Kang NW; Hong CS; Chen ZC; Chang WT
Diabetes; 2021 Jan; 70(1):262-267. PubMed ID: 33115828
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
